INM
InMed Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · CA
$1.75
+4.17%Margins
Gross margin
14.9%
EBITDA margin
-0.5%
EBIT margin
-0.5%
Net margin
-113.7%
FCF margin
-55.9%
195.2%
Return on equity
-179.3%
Return on assets
0.9%
Return on invested capital
3.15x
Asset turnover
-$1.2B
Cash from operations
$207
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Sep 1, 2026